Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Nicolas Roche; Vicente Plaza; Vibeke Backer; Job van der Palen; Isa Cerveri; Chelo Gonzalez; Guilherme Safioti; Irma Scheepstra; Oliver Patino; Dave Singh

doi:10.1038/s41533-019-0159-1

Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Nicolas Roche^*, Vicente Plaza, Vibeke Backer, Job van der Palen, Isa Cerveri, Chelo Gonzalez, Guilherme Safioti, Irma Scheepstra, Oliver Patino, Dave Singh

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

53 Downloads (Pure)

Abstract

Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).

Original language	English
Article number	1
Journal	NPJ primary care respiratory medicine
Volume	30
Issue number	1
DOIs	https://doi.org/10.1038/s41533-019-0159-1
Publication status	Published - 7 Jan 2020

Access to Document

10.1038/s41533-019-0159-1Licence: CC BY

Roche-2020-Asthma-control-and-copd-symptom-burFinal published version, 593 KBLicence: CC BY

Cite this

@article{9f3c608721cb4418b60ab573faf344cc,

title = "Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)",

abstract = "Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician{\textquoteright}s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).",

author = "Nicolas Roche and Vicente Plaza and Vibeke Backer and Palen, {Job van der} and Isa Cerveri and Chelo Gonzalez and Guilherme Safioti and Irma Scheepstra and Oliver Patino and Dave Singh",

year = "2020",

month = jan,

day = "7",

doi = "10.1038/s41533-019-0159-1",

language = "English",

volume = "30",

journal = "NPJ primary care respiratory medicine",

issn = "2055-1010",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

AU - Roche, Nicolas

AU - Plaza, Vicente

AU - Backer, Vibeke

AU - Palen, Job van der

AU - Cerveri, Isa

AU - Gonzalez, Chelo

AU - Safioti, Guilherme

AU - Scheepstra, Irma

AU - Patino, Oliver

AU - Singh, Dave

PY - 2020/1/7

Y1 - 2020/1/7

N2 - Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).

AB - Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).

UR - http://www.scopus.com/inward/record.url?scp=85077642015&partnerID=8YFLogxK

U2 - 10.1038/s41533-019-0159-1

DO - 10.1038/s41533-019-0159-1

M3 - Article

C2 - 31911607

AN - SCOPUS:85077642015

VL - 30

JO - NPJ primary care respiratory medicine

JF - NPJ primary care respiratory medicine

SN - 2055-1010

IS - 1

M1 - 1

ER -

Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this